Stockwatch: The impossible takes a little too long
This article was originally published in Scrip
Executive Summary
When Tony Blair joined Bill Clinton by satellite link to the White House in 2000 to announce the sequencing of the human genome, biotech stocks soared with the implication that genomics would result in a cure for any disease. Even today, nearly twelve years, recently approved targeted therapies for blood and skin cancers imply that the application of genomic data and molecular biology can result in a treatment for most unmet clinical needs, eventually.
You may also be interested in...
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.
Stock Watch: Pharma Businesses That Leave Consumer Behind
Healthcare conglomerates that divorce consumer, animal health and even generics businesses from their pure-play branded pharmaceutical groups could leave a less diversified and riskier sector in uncertain times. But the advantages are apparent.
Stock Watch: Acadia And Amylyx Trial Failures Were No Shock
The overused phrase ‘pipeline in a product’ translates to ‘disappointment in a product’ when the number of indications in the pipeline contracts towards zero.